IL1B and neoplasm: The prolonged inflammatory effects of IL-1β are counterbalanced by the action of the interleukin-1 receptor antagonist (IL-1RA) cytokine that competitively inhibits the binding of circulating IL-1β during an inflammatory event to quench acute inflammation and avoid tumor angiogenesis/metastasis.